nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

01.11.2017 | Original Article

BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma

verfasst von: Qi Liu, Hongda Zhu, Yun Liu, Sara Musetti, Leaf Huang

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Approximately, 50% of human melanomas are driven by BRAF mutations, which produce tumors that are highly immunosuppressive and often resistant to vaccine therapy. We introduced lipid-coated calcium phosphate nanoparticles (LCP NPs) as a carrier to efficiently deliver a tumor-specific antigen, the BRAF^V600E peptide, to drive dendritic cell (DC) maturation and antigen presentation in C57BL6 mice. The BRAF peptide vaccine elicited a robust, antigen-specific cytotoxic T cell response and potent tumor growth inhibition in a murine BRAF-mutant melanoma model. Advanced BRAF-specific immune response was illustrated by IFN-γ production assay and cytotoxic T lymphocyte (CTL) assay. Remodeling of immunosuppressive modules within the tumor microenvironment further facilitated CTL infiltration. Thus, using LCP NPs to deliver the BRAF peptide vaccine is a promising strategy for the BRAF-mutant melanoma therapy.

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30CrossRefPubMed

Gloster HM Jr, Brodland DG (1996) The epidemiology of skin cancer. Dermatol Surg 22(3):217–226CrossRefPubMed

Smyth MJ, Dunn GP, Schreiber RD (2006) Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90:1–50CrossRefPubMed

Miao L, Li J, Liu Q et al (2017) Transient and local expression of chemokine and immune checkpoint traps to treat pancreatic cancer. ACS Nano 11(9):8690–8706. doi:10.1021/acsnano.7b01786 CrossRefPubMed

Klemm F, Joyce JA (2015) Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol 25(4):198–213CrossRefPubMed

Sithanandam G, Kolch W, Duh FM et al (1990) Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies. Oncogene 5(12):1775–1780PubMed

Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516CrossRefPubMedPubMedCentral

Hauschild A, Grob JJ, Demidov LV et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358–365CrossRefPubMed

Long GV, Stroyakovskiy D, Gogas H et al (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371(20):1877–1888CrossRefPubMed

10.

Junttila MR, de Sauvage FJ (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501(7467):346–354CrossRefPubMed

11.

Rammensee H, Bachmann J, Emmerich NP et al (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50(3–4):213–219CrossRefPubMed

12.

Cintolo JA, Datta J, Xu S et al (2016) Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8 + T cells that impact BRAF-mutant murine melanoma. Melanoma Res 26(1):1–11CrossRefPubMed

13.

Guo X, Huang L (2012) Recent advances in nonviral vectors for gene delivery. Acc Chem Res 45(7):971–979CrossRefPubMed

14.

Liu Q, Das M, Liu Y et al (2017) Targeted drug delivery to melanoma. Adv Drug Deliv Rev. doi:10.1016/j.addr.2017.09.016

15.

Li J, Chen YC, Tseng YC et al (2010) Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release 142(3):416–421CrossRefPubMed

16.

Xu Z, Ramishetti S, Tseng YC et al (2013) Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. J Control Release 172(1):259–265CrossRefPubMed

17.

Reddy R, Zhou F, Nair S et al (1992) In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. J Immunol 148(5):1585–1589PubMed

18.

Czerkinsky CC, Nilsson LA, Nygren H et al (1983) A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 65(1–2):109–121CrossRefPubMed

19.

Chen WS, Xu PZ, Gottlob K et al (2001) Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 15(17):2203–2208CrossRefPubMedPubMedCentral

20.

Xu Z, Wang Y, Zhang L et al (2014) Nanoparticle-delivered transforming growth factor-beta siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano 8(4):3636–3645CrossRefPubMedPubMedCentral

21.

Lu Y, Miao L, Wang Y et al (2016) Curcumin micelles remodel tumor microenvironment and enhance vaccine activity in an advanced melanoma model. Mol Ther 24(2):364–374CrossRefPubMed

22.

Bamford S, Dawson E, Forbes S et al (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 91(2):355–358CrossRefPubMedPubMedCentral

23.

Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949–954CrossRefPubMed

24.

Pratilas CA, Taylor BS, Ye Q et al (2009) (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA 106(11):4519–4524CrossRefPubMedPubMedCentral

25.

Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene 22(20):3138–3151CrossRefPubMed

26.

Avril MF, Aamdal S, Grob JJ et al (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22(6):1118–1125CrossRefPubMed

27.

Crosby T, Fish R, Coles B et al (2002) Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. doi:10.1002/14651858.CD001215

28.

Falkson CI, Ibrahim J, Kirkwood JM et al (1998) Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 16(5):1743–1751CrossRefPubMed

29.

Middleton MR, Grob JJ, Aaronson N et al (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18(1):158–166CrossRefPubMed

30.

Mocellin S, Pasquali S, Rossi CR et al (2010) Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102(7):493–501CrossRefPubMed

31.

Theofilopoulos AN, Baccala R, Beutler B et al (2005) Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23:307–336CrossRefPubMed

32.

Schwartzentruber DJ, Lawson DH, Richards JM et al (2011) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364(22):2119–2127CrossRefPubMedPubMedCentral

33.

Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723CrossRefPubMedPubMedCentral

34.

Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521–2532CrossRefPubMed

35.

Hassel JC (2016) Ipilimumab plus nivolumab for advanced melanoma. Lancet Oncol 17(11):1471–1472CrossRefPubMed

36.

Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122–133CrossRefPubMedPubMedCentral

37.

Schadendorf D, Hodi FS, Robert C et al (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33(17):1889–1894CrossRefPubMedPubMedCentral

38.

Topalian SL, Taube JM, Anders RA et al (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16(5):275–287CrossRefPubMedPubMedCentral

39.

Miao L, Guo S, Lin CM et al (2017) Nanoformulations for combination or cascade anticancer therapy. Adv Drug Deliv Rev 115:3–22CrossRefPubMed

40.

Nelson CM, Bissell MJ (2006) Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol 22:287–309CrossRefPubMedPubMedCentral

41.

Conniot J, Silva JM, Fernandes JG et al (2014) Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. Front Chem 2:105CrossRefPubMedPubMedCentral

42.

Miao L, Liu Q, Lin CM et al (2017) Targeting tumor-associated fibroblasts for therapeutic delivery in desmoplastic tumors. Cancer Res 77(3):719–731CrossRefPubMed

43.

Hu K, Miao L, Goodwin TJ et al (2017) Quercetin remodels the tumor microenvironment to improve the permeation, retention, and antitumor effects of nanoparticles. ACS Nano 11(5):4916–4925CrossRefPubMed

44.

Andreatta M, Nielsen M (2016) Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics 32(4):511–517CrossRefPubMed

45.

Nielsen M, Lundegaard C, Worning P et al (2003) Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 12(5):1007–1017CrossRefPubMedPubMedCentral

46.

Tseng YC, Xu Z, Guley K et al (2014) Lipid-calcium phosphate nanoparticles for delivery to the lymphatic system and SPECT/CT imaging of lymph node metastases. Biomaterials 35(16):4688–4698CrossRefPubMedPubMedCentral

47.

Medzhitov R, Janeway CA Jr (2002) Decoding the patterns of self and nonself by the innate immune system. Science 296(5566):298–300CrossRefPubMed

48.

Umansky V, Sevko A (2013) Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron 6(2):169–177CrossRefPubMed

49.

Lo A, Wang LC, Scholler J et al (2015) Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells. Cancer Res 75(14):2800–2810CrossRefPubMedPubMedCentral

50.

Rigel DS, Carucci JA (2005) Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA Cancer J Clin 50(4):215–236 quiz 237-40 CrossRef

51.

Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12(4):269–281CrossRefPubMed

52.

Porter DL, Levine BL, Kalos M et al (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365(8):725–733CrossRefPubMedPubMedCentral

53.

Allen TM, Cullis PR (2004) Drug delivery systems: entering the mainstream. Science 303(5665):1818–1822CrossRefPubMed

Titel: BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma
verfasst von: Qi Liu
Hongda Zhu
Yun Liu
Sara Musetti
Leaf Huang
Publikationsdatum: 01.11.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 2/2018
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-017-2079-7

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

CXCL13 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer

Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells

A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice

Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?

Absolute lymphocyte counts at end of induction correlate with distinct immune cell compartments in pediatric B cell precursor acute lymphoblastic leukemia

Clinicopathologic implications of CD8+/Foxp3+ ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie